MT2A

Overview

MT2A is a member of the metallothionein protein family involved in metal ion homeostasis and cellular protection against oxidative stress. In HER2+ metastatic esophagogastric cancer, MT2A was identified as part of a trastuzumab resistance transcriptional program by single-cell RNA-seq analysis.

Alterations observed in the corpus

  • MT2A expression associated with trastuzumab + chemotherapy resistance by scRNA-seq in HER2+ esophagogastric cancer (EGC) escape lesions; identified alongside MT1H, MT1E, and MSMB as candidate future therapeutic targets PMID:37406106.

Cancer types (linked)

  • Esophagogastric cancer (HER2+) — MT2A expressed in resistance subpopulations at progression on trastuzumab-based therapy PMID:37406106.

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • MT2A is a candidate future therapeutic target in HER2+ EGC resistance; requires orthogonal preclinical validation PMID:37406106.

Open questions

  • The mechanism by which the metallothionein resistance program (MT1H, MT1E, MT2A, MSMB) drives trastuzumab resistance requires functional characterization.

Sources

This page was processed by crosslinker on 2026-05-04.